2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04172792 (ClinicalTrials.gov) | November 26, 2019 | 19/11/2019 | Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS) | Safety and Tolerability of Fat-rich vs. Carbohydrate-rich High-caloric Food Supplements in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Dietary Supplement: high-caloric fatty diet;Dietary Supplement: ultra-high-caloric fatty diet;Dietary Supplement: ultra-high-caloric carbohydrate-rich diet | Albert Christian Ludolph, Prof. | Nutritia GmbH, 91052 Erlangen, Germany | Completed | 18 Years | N/A | All | 64 | Phase 1 | Germany |